Last reviewed · How we verify
Silybin
Silybin, marketed by University Magna Graecia, is an established drug with a key composition patent expiring in 2028. The drug's primary strength lies in its current market presence, leveraging its marketed status to maintain a steady revenue stream. The primary risk is the patent expiry in 2028, which could lead to increased competition from generics.
At a glance
| Generic name | Silybin |
|---|---|
| Also known as | Siliphos, Milk thistle, Advanced hepatocellular carcinoma |
| Sponsor | University Magna Graecia |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Silibinin in Association With Concomitant Chemoradiotherapy and Maintenance Temozolomide in STAT3 Positive IDH Wild-type, Newly Diagnosed Glioblastoma Patients (NA)
- Effect of the Combination of Pterostilbene Cocrystal With Silybin and Nicotinamide Riboside on Exercise-Induced Oxidative Stress (NA)
- A Prospective Cohort Study on Drug-induced Liver Injury in China（DILI-P）
- Prospective Double Arm Randomized Trial: WBRT Alone and WBRT Plus Silibinin (NA)
- Plasma Exchange for Amanita Toxin-induced Acute Liver Failure
- Effect of L-ornithine-L-aspertate (LOLA) on the Gut Microbiome (PHASE4)
- Silymarin for the Prevention of Atrial Fibrillation After Cardiac Surgery (PHASE3)
- An Intervention Study of Compound Silymarin in Patients With Non-alcoholic Fatty Liver Disease (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Silybin CI brief — competitive landscape report
- Silybin updates RSS · CI watch RSS
- University Magna Graecia portfolio CI